Borosil Scientific (BOROSCI) unveils 20-tonne-per-day glass tubing furnace alongside Rs 60cr glassware expansion

Borosil Scientific Limited (NSE: BOROSCI, BSE: 544184) has approved an investment of up to ₹70 crore to establish a borosilicate 3.3 glass tubing furnace at its Bharuch manufacturing facility in Gujarat, targeting commercial production by 31 March 2028. Announced on 28 October 2026, the project will create approximately 20 metric tonnes of daily tubing capacity, allowing the company to manufacture a raw material currently sourced from overseas suppliers. The decision complements a separate ₹60 crore glassware capacity expansion scheduled for commissioning by March 2027, bringing the two disclosed manufacturing investment programmes to an indicative combined outlay of up to ₹130 crore. However, although consolidated second-quarter profit increased approximately 86%, standalone earnings declined and the company’s shares remained close to their annual lows, making the economics of backward integration more important than the capacity announcement itself.

The latest investment marks a strategic extension of Borosil Scientific’s manufacturing value chain rather than a conventional expansion of finished laboratory glassware output. By producing borosilicate glass tubing internally, management aims to improve raw material availability, quality control and manufacturing cost efficiency. The potential benefit extends across its scientific glassware and pharmaceutical packaging activities, although actual savings will depend on furnace utilisation, production yields, energy costs and the proportion of imported tubing eventually replaced.

Why is Borosil Scientific investing ₹70 crore in a borosilicate glass tubing furnace at Bharuch?

Borosil Scientific’s board approved the proposed furnace on 28 October 2026 as part of its manufacturing development strategy. The facility will have an installed production capacity of approximately 20 metric tonnes per day and will be established at the company’s existing Bharuch manufacturing location. Commercial production is expected to commence by 31 March 2028, subject to project implementation and commissioning requirements.

The investment is intended primarily for captive consumption. Borosil Scientific currently procures glass tubing from overseas suppliers for use in various finished glassware products, making the business dependent on external availability, import logistics and international procurement conditions. Establishing domestic production would allow management to exercise greater control over the timing, quality and availability of a critical manufacturing input.

The company has also indicated that surplus tubing could be sold to external customers. However, the project should not be interpreted primarily as a new standalone revenue business because its disclosed purpose is to supply existing internal manufacturing requirements. External sales would depend on available production after captive consumption, customer specifications and the commercial attractiveness of selling surplus material.

The proposed furnace represents a new production capability within the company. Its exchange disclosure records existing glass tubing furnace capacity as nil, meaning the 20-tonne-per-day figure is a planned addition rather than an increase from an already operating captive tubing line. The announcement does not establish that construction has commenced or that the necessary equipment has been installed.

Management plans to fund the project through internal accruals and/or borrowings. It has not disclosed a definitive financing split, expected annual cost savings, product-level return assumptions or estimated payback period. Those details will determine how efficiently the ₹70 crore investment contributes to the company’s profitability once production begins.

How could backward integration reduce Borosil Scientific’s dependence on imported glass tubing?

Borosilicate 3.3 glass is valued in laboratory and industrial applications because of its thermal characteristics and chemical resistance. Tubing manufactured from this material provides a starting input for products such as laboratory vessels, specialised scientific glassware and certain pharmaceutical packaging formats. Manufacturing quality and consistency are particularly relevant where finished products must comply with dimensional, thermal or chemical specifications.

Borosil Scientific currently purchases tubing from overseas suppliers before converting it into finished products at its manufacturing facilities. That arrangement exposes the business to international procurement conditions, including changes in supplier prices, transportation costs, delivery schedules and currency movements. The company’s October investor presentation identified higher input costs associated with geopolitical tensions in the Middle East as one factor affecting standalone profitability during the September quarter.

Backward integration could change those economics by moving an important part of the manufacturing process within the company’s direct control. Captive tubing production may reduce certain procurement and transportation costs, limit dependence on external suppliers and improve coordination between raw material production and finished glassware manufacturing.

However, the investment will also introduce new operating requirements. Glass furnaces are capital-intensive industrial assets that require energy, maintenance, process control and technically consistent production. The economic advantage of producing tubing internally will depend on whether the total manufacturing cost is competitive with the landed cost of imported material.

The company has not disclosed its current annual glass tubing consumption or the proportion of imports that the proposed furnace could replace. It would therefore be premature to describe the investment as eliminating import dependence. The actual degree of substitution will also depend on the range of tubing dimensions and specifications that the new facility can manufacture commercially.

The strongest financial evidence will emerge after commissioning, when Borosil Scientific can compare internal tubing production costs, procurement savings and manufacturing yields against its previous sourcing arrangements. Lower dependence on imported inputs would improve supply-chain flexibility, but sustainable margin benefits will require efficient production and sufficient capacity utilisation.

How does the ₹70 crore furnace fit alongside Borosil Scientific’s separate ₹60 crore glassware capacity expansion?

The tubing furnace is part of a wider investment cycle at Bharuch. Borosil Scientific’s 31 October investor presentation identifies a separate ₹60 crore glassware manufacturing expansion intended to increase annual production capacity from approximately 15 lakh units to 108 lakh units. The project is targeted for commercial production by March 2027, a year ahead of the proposed tubing furnace.

The planned increase represents an additional 93 lakh units annually, or approximately 6.2 times the current installed capacity. Existing utilisation for the glassware operation was disclosed at approximately 87%, indicating that the company has been operating a substantial proportion of its available manufacturing capability.

The two projects serve different positions within the production chain. The ₹60 crore programme expands finished glassware manufacturing capacity, while the ₹70 crore furnace will manufacture the glass tubing used as an input for various products. The distinction is important because the output of one project is measured in units of finished glassware and the other in tonnes of raw material.

Management has identified increasing demand from Borosil Limited and the expected expansion of laboratory glassware requirements as reasons for the finished-glassware investment. The planned manufacturing capacity could support higher production volumes, provided customer orders and distribution channels absorb the additional output.

The difference in commissioning timelines also creates a transitional requirement. Finished glassware capacity is scheduled to expand by March 2027, whereas captive tubing production is not expected until March 2028. During that interval, the company may continue relying on externally sourced tubing to support increased finished-product manufacturing.

The two separately disclosed projects have a combined indicative capital outlay of up to ₹130 crore. That represents approximately 27.8% of Borosil Scientific’s FY26 consolidated revenue of ₹467.34 crore, illustrating the scale of the proposed investments relative to its existing business.

The figure represents planned capital expenditure, not spending already completed. Their financial contribution will also emerge at different times, depending on commissioning, manufacturing utilisation and commercial demand.

What do Borosil Scientific’s Q2 FY27 results reveal about the gap between consolidated and standalone profitability?

Borosil Scientific reported consolidated revenue from operations of ₹114.96 crore for the quarter ended 30 September 2026, compared with ₹106.90 crore in the corresponding period of FY26. Revenue increased approximately 7.5%, while company-reported EBITDA rose 29.4% to ₹11 crore from ₹8.5 crore.

The consolidated EBITDA margin improved from 8% to 9.6%, representing an increase of approximately 160 basis points. Profit after tax rose from ₹2.85 crore to ₹5.31 crore, an increase of approximately 86%. The results demonstrate stronger group-level profitability despite relatively modest revenue growth.

However, the standalone business presented a different picture. Standalone revenue increased 4.7% to ₹104.19 crore, but EBITDA declined approximately 9.7% to ₹11.7 crore. The standalone EBITDA margin fell from 13.1% to 11.3%, while profit after tax declined 16.9% to ₹6.25 crore.

The divergence indicates that consolidated earnings growth was not primarily driven by stronger profitability in the company’s core standalone manufacturing operations. Management attributed the improvement in group results partly to stronger performance at its subsidiary, Goel Scientific Glass Works Limited, where sales increased 28.7% to approximately ₹11.2 crore.

The subsidiary’s loss before tax narrowed from approximately ₹4.8 crore to ₹1.1 crore. The substantial reduction in losses helped improve consolidated profitability, even as higher input costs affected the standalone business.

Management specifically identified geopolitical tensions in the Middle East as contributing to elevated input costs. It expects profitability to improve as conditions stabilise and has indicated that initiatives are being undertaken to limit the impact. Those expectations remain dependent on future procurement and manufacturing conditions.

The latest furnace investment addresses part of this cost-exposure problem by seeking to localise production of an important input. However, the furnace is not scheduled to begin commercial production until March 2028, meaning it cannot explain the September-quarter earnings improvement or provide an immediate remedy for current manufacturing pressures.

Why is Borosil Scientific’s pharmaceutical packaging business still reporting losses despite higher sales?

The company’s latest financial statements provide a more detailed view of its operating portfolio following a change in segment reporting. During the September quarter, Borosil Scientific reorganised its reportable businesses into Scientific, Primary Pharma Packaging and Consumer Glassware segments. Previous-period figures were restated to reflect the revised structure.

The Scientific segment, comprising laboratory glassware, laboratory equipment and process systems, generated consolidated revenue of approximately ₹79.05 crore during Q2 FY27. This represented growth of 8.3% from ₹72.99 crore a year earlier and accounted for nearly 69% of group revenue.

Primary Pharma Packaging revenue increased 21.4% to approximately ₹20.96 crore, compared with ₹17.26 crore in Q2 FY26. Despite the sales increase, the segment reported a loss before tax and unallocated items of approximately ₹2.60 crore, improving from a loss of ₹5.13 crore a year earlier.

The reduced loss indicates operational improvement, but the business has not yet reached segment-level profitability. Its products include tubular glass vials and ampoules used in pharmaceutical packaging, where manufacturing consistency, quality requirements and customer specifications influence operating costs.

The proposed tubing furnace could eventually support the packaging business through greater control over raw material supply. However, it has not been established how much of the furnace’s output will be allocated to pharmaceutical packaging or which specific product lines could benefit.

The Consumer Glassware segment delivered a weaker sales performance. Revenue declined approximately 10.2% year on year to ₹14.96 crore, while the segment’s reported result fell to about ₹0.78 crore from ₹1.06 crore.

These differences show why the company’s manufacturing investment strategy must be evaluated across several business categories. Laboratory products remain the largest revenue contributor, pharmaceutical packaging is growing but loss-making, and consumer glassware faces weaker sales. The benefits of backward integration may therefore vary significantly according to the products manufactured and their respective cost structures.

How are laboratory equipment and process systems changing Borosil Scientific’s revenue mix?

Borosil Scientific’s scientific portfolio is expanding beyond traditional laboratory glassware into equipment and industrial process systems. The company’s October presentation reported laboratory consumables revenue of ₹55.3 crore during Q2 FY27, up 2.2% from ₹54.2 crore a year earlier. Laboratory equipment revenue remained broadly unchanged at ₹11.3 crore.

Process systems delivered a much stronger increase, with quarterly revenue rising approximately 64.6% to ₹12.4 crore from ₹7.6 crore. During the first half of FY27, process systems revenue increased 36.1% to ₹21 crore, making it one of the fastest-growing disclosed categories within the scientific portfolio.

The company has developed its process systems business through specialised glass equipment and its acquisition of Goel Scientific Glass Works Limited. The portfolio includes laboratory and industrial process equipment used in chemical and pharmaceutical applications.

The commercial importance of this diversification lies in the potential to supply customers with higher-value systems alongside conventional consumables. Laboratory glassware can generate repeat demand through replacement and routine usage, while process systems and equipment may involve larger individual orders, installation requirements and specialised technical support.

However, the revenue profile of these categories can differ. Equipment and process systems may depend on project timing and customer capital expenditure, whereas consumables are more closely linked to recurring laboratory activity. A broader portfolio provides additional opportunities for growth but also introduces different sales and execution characteristics.

Management has established a medium-term revenue growth objective of approximately 12% to 14% annually. Achieving that target would require faster growth than the 9.3% consolidated sales increase reported during the first half of FY27, although individual periods can vary according to customer demand and product mix.

The manufacturing expansion at Bharuch is intended to strengthen the company’s production foundation, while equipment and process systems provide additional routes for revenue growth. Their combined financial impact will depend on demand, product mix and the operating margins achieved across the portfolio.

Can Borosil Scientific finance ₹130 crore of manufacturing investments without increasing balance-sheet risk significantly?

Borosil Scientific’s balance sheet provides a relatively strong starting point for the proposed capital expenditure. According to its October investor presentation, the group reported consolidated net cash of approximately ₹129.5 crore at 30 September 2026, compared with ₹107.6 crore a year earlier. The presentation expresses net debt as a negative number, indicating that cash and relevant financial resources exceeded borrowings under the company’s calculation.

The positive net cash position provides financial flexibility, but it does not establish that the entire amount is available for unrestricted investment. Cash balances, financial investments, working capital requirements and other obligations must be considered when assessing how much expenditure can be funded internally.

The group generated approximately ₹17.3 crore of net cash from operating activities during H1 FY27, compared with ₹7.75 crore in the corresponding period of FY26. The improvement reflected stronger operating cash generation during the first half.

However, payments towards property, plant and equipment and intangible assets reached approximately ₹20.29 crore during the same period, compared with ₹10.08 crore a year earlier. Capital expenditure consequently exceeded net operating cash generation by roughly ₹3 crore before considering other investing and financing activities.

The relationship between operating cash flow and investment expenditure will become more important as the glassware expansion and tubing furnace progress. The two projects have different commissioning deadlines, meaning their funding requirements may be spread across multiple reporting periods rather than arising simultaneously.

Borosil Scientific has indicated that both investments may be financed through internal accruals and/or borrowings. The actual funding mix will determine whether the company maintains its net cash position or introduces additional financial leverage.

The investment could be commercially justified if higher manufacturing volumes and procurement savings generate attractive returns on the deployed capital. Conversely, lower utilisation or higher operating expenses could reduce the expected profitability even if the projects are completed within their approved budgets.

A useful test will be whether the company can sustain operating cash generation as investment expenditure increases, without allowing new projects to weaken its overall financial flexibility disproportionately.

Could the Viksit Gujarat Industrial Policy 2026 improve the economics of Borosil Scientific’s Bharuch investments?

Borosil Scientific has indicated that it intends to seek applicable subsidy benefits under the Viksit Gujarat Industrial Policy 2026 for eligible investment associated with its manufacturing projects. The proposed support is relevant because industrial incentives can influence the effective cost of capital investment and the returns generated by new manufacturing assets.

However, the company’s intention to apply for incentives should not be interpreted as approval or receipt of financial assistance. The availability and amount of benefits will depend on eligibility criteria, applicable policy provisions and decisions by the relevant authorities.

The company has not disclosed a confirmed subsidy amount for the ₹70 crore tubing furnace or the separate ₹60 crore glassware expansion. It would therefore be inappropriate to reduce the stated project costs by an assumed incentive when estimating returns.

Even without confirmed subsidies, the investments support the broader objective of increasing domestic industrial manufacturing capability. Replacing imported glass tubing with locally produced material could reduce certain international supply-chain dependencies and increase the availability of a technically important input within India.

The commercial outcome will nevertheless depend on operating economics rather than policy support alone. Energy costs, production yields, customer specifications and stable utilisation will influence the competitiveness of domestically manufactured tubing.

Any approved subsidy would improve the project economics to the extent permitted under the applicable scheme, but the investment case must remain viable against realistic manufacturing costs and demand assumptions.

Why are Borosil Scientific shares near their 52-week lows despite stronger consolidated earnings?

Borosil Scientific shares closed at approximately ₹104.07 on the National Stock Exchange of India on 2 November 2026, recovering around 2.3% from the previous close of ₹101.73. The stock nevertheless remained approximately 42.4% below its 52-week high of ₹180.80, reached in June 2026.

The corresponding 52-week low stood at ₹96.64, leaving the latest closing price only about 7.7% above that level. The substantial decline from the annual peak indicates that the company’s equity valuation has weakened despite ongoing manufacturing investments and the improvement in consolidated second-quarter earnings.

The share-price reaction following the October results was also mixed. The stock closed at ₹109.40 on 28 October, before declining to ₹103.27 on 29 October and ₹101.73 on 30 October. The cumulative fall of approximately 7% across those two sessions coincided with the earnings and capacity disclosures, although the movement cannot be attributed conclusively to any single announcement.

At the 2 November closing price, Borosil Scientific had an equity market capitalisation of approximately ₹926 crore. That valuation was equivalent to roughly twice the company’s FY26 consolidated revenue of ₹467.34 crore, although a revenue multiple alone does not establish whether the shares are attractively priced.

The financial results provide contrasting signals for investors. Consolidated EBITDA and profit improved, but standalone margins contracted, pharmaceutical packaging remained loss-making and consumer glassware revenue declined. The reduction in subsidiary losses also contributed substantially to the improvement in group profitability.

The ₹70 crore furnace offers a potential route to better manufacturing economics, but its expected commissioning date is still more than a year away. The share price therefore reflects a business whose longer-term industrial strategy is developing while the benefits of its investment programme remain largely unproven.

A sustained improvement in valuation would be more convincingly supported by stronger core manufacturing margins, continued recovery in pharmaceutical packaging profitability and evidence that new production capacity is being absorbed commercially.

What milestones will show whether Borosil Scientific’s Bharuch investment creates lasting shareholder value?

The first significant milestone will be the planned commissioning of the ₹60 crore glassware expansion by March 2027. The project aims to increase installed capacity from approximately 15 lakh to 108 lakh units annually, creating a substantial increase in potential output. Commercial utilisation after commissioning will determine whether the additional capacity contributes meaningfully to revenue and operating earnings.

The second milestone will be construction and commissioning of the proposed 20-tonne-per-day borosilicate glass tubing furnace by 31 March 2028. Progress on equipment installation, project expenditure and production readiness will help establish whether the ₹70 crore investment remains on schedule.

After commissioning, the most important operational measures will include tubing output, manufacturing yield, captive consumption and changes in raw material procurement costs. These indicators will show whether the company is successfully replacing imported supplies and improving the economics of its finished-product manufacturing operations.

Management’s medium-term objective of 12% to 14% annual revenue growth provides an additional financial benchmark. The group achieved 9.3% revenue growth during H1 FY27, while consolidated EBITDA increased 37.8%. Sustaining faster earnings growth will depend on preserving operating improvements rather than relying exclusively on the reduction of subsidiary losses.

The latest financial results also establish a specific profitability challenge. Standalone EBITDA margin declined to 11.3% from 13.1% a year earlier, making margin recovery an important indicator before the new tubing furnace becomes operational.

Borosil Scientific’s manufacturing strategy has a defined industrial rationale: increase finished glassware capacity, localise a critical input and reduce exposure to external supply conditions. Its net cash position provides a degree of financial flexibility, while the growing process systems business creates additional revenue opportunities beyond conventional glassware.

The next phase will test whether these investments can strengthen profitability rather than simply increase manufacturing assets. Higher capacity utilisation, better procurement economics and sustained operating cash generation would support the strategy, while commissioning delays or persistently weak margins would reduce expected returns.

The clearest evidence of value creation will emerge when Borosil Scientific demonstrates that the expanded glassware operation can generate profitable incremental sales and that the subsequent tubing furnace can supply material at a competitive cost. Until those milestones are achieved, the ₹130 crore combined investment programme represents a potentially valuable manufacturing opportunity rather than a realised earnings improvement.

What should investors know about Borosil Scientific’s ₹70 crore Bharuch furnace, Q2 FY27 earnings and share-price decline?

• Borosil Scientific Limited approved a ₹70 crore borosilicate 3.3 glass tubing furnace at Bharuch on 28 October 2026, targeting commercial production by March 2028.
• The proposed furnace will have installed capacity of approximately 20 metric tonnes per day, primarily for captive consumption, with potential external sales of surplus output.
• The company currently imports glass tubing, making domestic production a potential route to improved supply reliability, quality control and manufacturing cost efficiency.
• A separate ₹60 crore glassware project aims to increase annual capacity from approximately 15 lakh to 108 lakh units by March 2027.
• Consolidated Q2 FY27 revenue increased 7.5% to ₹114.96 crore, while EBITDA rose 29.4% and profit after tax increased approximately 86% to ₹5.31 crore.
• Standalone EBITDA declined 9.7% and profit after tax fell 16.9%, reflecting pressure on core manufacturing profitability.
• Primary Pharma Packaging revenue increased 21.4%, although the segment continued reporting losses, while Consumer Glassware revenue declined 10.2%.
• The group reported net cash of approximately ₹129.5 crore at September 2026, providing financial flexibility alongside increasing manufacturing expenditure.
• Borosil Scientific shares closed around ₹104.07 on 2 November, approximately 42.4% below their June 2026 annual high.
• The March 2027 glassware expansion and March 2028 tubing furnace commissioning will provide important milestones for evaluating manufacturing utilisation, cost savings and future returns.